¬á¬à¬Õ¬Ó¬Ö¬ã¬ß¬Ñ¬ñ ¬ä¬å¬Þ¬Ò¬Ñ 120 ¬ã¬Þ mobi ¬Ó ¬Ú¬ß¬ä¬Ö¬â¬ß¬Ö¬ä-¬Þ¬Ñ¬Ô¬Ñ¬Ù¬Ú¬ß¬Ö ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬ß¬Ú¬Ü¬Ú ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬Ý¬Ú¬Õ¬Ö¬â | ||||||||||
SansillEvato | 2022-05-31 | 184 | ||||||||
¬Ü¬å¬ç¬ß¬ñ ¬Ó ¬ã¬ä¬Ú¬Ý¬Ö ¬Þ¬à¬Õ¬Ö¬â¬ß ¬Ó ¬Þ¬Ñ¬Ô¬Ñ¬Ù¬Ú¬ß¬Ö ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬Ý¬Ú¬Õ¬Ö¬â Tegs: ¬Þ¬Ñ¬Ü¬ã¬Ú¬Þ ¬ä¬å¬â¬ã¬Ü¬Ú¬Û ¬Ó ¬Þ¬Ñ¬Ô¬Ñ¬Ù¬Ú¬ß¬Ö ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬Ý¬Ú¬Õ¬Ö¬â https://santehlider.com/company/staff/maksim-turskiy/ ¬á¬à¬Õ¬Ó¬Ö¬ã¬ß¬Ñ¬ñ ¬ä¬å¬Þ¬Ò¬Ñ 120 ¬ã¬Þ mobi ¬Ó ¬Ú¬ß¬ä¬Ö¬â¬ß¬Ö¬ä-¬Þ¬Ñ¬Ô¬Ñ¬Ù¬Ú¬ß¬Ö ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬ß¬Ú¬Ü¬Ú ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬Ý¬Ú¬Õ¬Ö¬â ¬á¬à¬Õ¬Ó¬Ö¬ã¬ß¬Ñ¬ñ ¬ä¬å¬Þ¬Ò¬Ñ 120 ¬ã¬Þ mobi ¬Ó ¬Ú¬ß¬ä¬Ö¬â¬ß¬Ö¬ä-¬Þ¬Ñ¬Ô¬Ñ¬Ù¬Ú¬ß¬Ö ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬ß¬Ú¬Ü¬Ú ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬Ý¬Ú¬Õ¬Ö¬â ¬á¬à¬Õ¬Ó¬Ö¬ã¬ß¬Ñ¬ñ ¬ä¬å¬Þ¬Ò¬Ñ 120 ¬ã¬Þ mobi ¬Ó ¬Ú¬ß¬ä¬Ö¬â¬ß¬Ö¬ä-¬Þ¬Ñ¬Ô¬Ñ¬Ù¬Ú¬ß¬Ö ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬ß¬Ú¬Ü¬Ú ¬ã¬Ñ¬ß¬ä¬Ö¬ç¬Ý¬Ú¬Õ¬Ö¬â |
18586 | endostatin murine, recombinant ¬Ü¬å¬á¬Ú¬ä¬î ¬à¬ß¬Ý¬Ñ... | LavillEvat | 2024-04-03 | 3 | |
18585 | anti-histone deacetylase 1 (hdac1) anti& ¬Ü¬å¬á¬Ú¬ä... | LavillEvat | 2024-03-31 | 4 | |
18584 | First revalidation, dilatation ptosis accountability... | axojaqeera | 2024-01-05 | 31 | |
18583 | L, documentation rotational, expressed accountabilit... | axojaqeera | 2024-01-05 | 31 | |
18582 | ¬Ü¬à¬Ý¬à¬ß¬Ü¬Ñ ¬Õ¬Ý¬ñ ¬Ó¬ï¬Ø¬ç caprisil c18 5 ¬Þ¬Ü¬Þ... | LavillEvat | 2023-10-28 | 65 | |
18581 | pyrex(r) vista(tm) volumetric pipette, & ¬Ü¬å¬á¬Ú¬ä... | LavillEvat | 2023-10-18 | 59 | |
18580 | 5-chloro-2-[(4-fluorobenzyl)oxy]benzoyl chloride †... | LavillEvat | 2023-10-13 | 65 | |
18579 | human gabrr1 gene orf cdna clone expression plasmid ... | LavillEvat | 2023-10-07 | 69 | |
18578 | Consider rehabilitating total symptom memory, append... | eshuhia | 2023-09-22 | 75 | |
18577 | Consider case-control crescent higher, health-relate... | eshuhia | 2023-09-22 | 69 | |
1 2 3 4 5 6 7 8 9 10 |